TAK 070

Drug Profile

TAK 070

Alternative Names: TAK-070

Latest Information Update: 17 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer University of Tokyo
  • Class Antidementias
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 11 Mar 2013 Phase-I clinical trials in Alzheimer's disease (in the elderly, in volunteers) in Japan (PO)
  • 08 Jun 2012 TAK 070 licensed to the University of Tokyo
  • 26 Jul 2004 Preclinical trials in Alzheimer's disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top